Cargando…
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
BACKGROUND: The optimal treatment strategy for resectable BRAF V600E mutant colorectal oligometastases (CRM) has not been established due to the rarity and rapid progression of the disease. Since the unresectable recurrence rate is high, development of novel perioperative therapies are warranted. On...
Autores principales: | Kobayashi, Shin, Bando, Hideaki, Taketomi, Akinobu, Takamoto, Takeshi, Shinozaki, Eiji, Shiozawa, Manabu, Hara, Hiroki, Yamazaki, Kentaro, Komori, Koji, Matsuhashi, Nobuhisa, Kato, Takeshi, Kagawa, Yoshinori, Yokota, Mitsuru, Oki, Eiji, Komine, Keigo, Takahashi, Shinichiro, Wakabayashi, Masashi, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440878/ https://www.ncbi.nlm.nih.gov/pubmed/37605122 http://dx.doi.org/10.1186/s12885-023-11311-5 |
Ejemplares similares
-
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020) -
Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019) -
Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022) -
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022) -
Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)